BridgeBio Oncology Therapeutics Unveils Promising BBO-10203 Breast Cancer Data at SABCS
Reuters
Oct 31
BridgeBio Oncology <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Unveils Promising BBO-10203 Breast Cancer Data at SABCS
BridgeBio Oncology Therapeutics Inc. has announced two upcoming poster presentations at the San Antonio Breast Cancer Symposium (SABCS), to be held December 9-12, 2025. The company will share new data on BBO-10203, a first-in-class, orally bioavailable, selective breaker of the RAS:PI3Kα interaction. The first poster will present pre-clinical results showing that BBO-10203 inhibits tumor growth alone and in combination with fulvestrant or ribociclib in breast cancer models, without inducing hyperglycemia. The second poster will provide details on BREAKER-101, an ongoing phase 1a/1b open-label clinical trial evaluating the safety, tolerability, pharmacokinetics, and efficacy of BBO-10203 in patients with advanced solid tumors. The results from these studies will be presented at the symposium and have not yet been publicly disclosed.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bridgebio Oncology Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9565897-en) on October 30, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.